Page last updated: 2024-10-16

carnitine and Seizures

carnitine has been researched along with Seizures in 41 studies

Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.

Research Excerpts

ExcerptRelevanceReference
"Warnings of L-carnitine induced seizures are recorded on product monographs and pharmacy databases, without any referenced literature."8.93Levocarnitine induced seizures in patients on valproic acid: A negative systematic review. ( Gillman, LM; Sader, N; West, M; Zeiler, FA, 2016)
"When ddY mice were pretreated with L-carnitine (5, 10 or 20 mmol/kg), clonic as well as tonic seizures induced by pentylenetetrazol (PTZ) were dose-dependently suppressed."7.69Suppression of pentylenetetrazol-induced seizures by carnitine in mice. ( Igisu, H; Ikeda, M; Iryo, Y; Matsuoka, M; Yu, Z, 1997)
"Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most prevalent encephalopathy in Japanese children."5.51Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study. ( Fukui, KO; Ishiguro, A; Kashii, H; Kubota, M; Terashima, H, 2019)
"No further seizures were noted by day 5."5.51A newborn with seizures born to a mother diagnosed with primary carnitine deficiency. ( Chen, S; Hu, Y; Huang, Y; Lin, J; Lin, Z; Nan, Y; Zhou, X, 2019)
"Valproic acid is a broad-spectrum anticonvulsant that has also gained attention in the psychiatric setting."5.46L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report. ( Fagiolino, P; Guevara, N; Maldonado, C; Silveira, A; Vázquez, M, 2017)
"Carnitine levels in CSF were 1/10 compared with serum in normal febrile children."5.30CSF levels of carnitine in children with meningitis, neurologic disorders, acute gastroenteritis, and seizure. ( Gruener, N; Lerner, A; Shinawi, M, 1998)
"Warnings of L-carnitine induced seizures are recorded on product monographs and pharmacy databases, without any referenced literature."4.93Levocarnitine induced seizures in patients on valproic acid: A negative systematic review. ( Gillman, LM; Sader, N; West, M; Zeiler, FA, 2016)
"Valproic acid is approved for treatment of seizures and manic episodes of bipolar disorder, and continues to be one of the most commonly prescribed antiepileptic drugs in the world."4.90Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity. ( Felker, D; Johnson, DE; Lynn, A; Wang, S, 2014)
"We report the case of an aborted awake craniotomy for a left frontotemporoinsular glioma due to ammonia encephalopathy on a patient taking Levetiracetam, valproic acid and clobazam."3.81Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy. ( Arroyo Pérez, R; Fernández-Candil, JL; León Jorba, A; Pacreu Terradas, S; Villalba Martínez, G; Vivanco-Hidalgo, RM, 2015)
"This prospective study was designed to investigate whether or not monotherapy with sodium valproate (VPA) or oxcarbazepine (OXC) affects plasma levels of fatty acylcarnitine esters in children with epilepsy."3.77Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine. ( Biberoglu, G; Cansu, A; Ezgu, FS; Hasanoglu, A; Hirfanoglu, TL; Serdaroglu, A; Tumer, L, 2011)
" Laboratory data showed hypoglycemia and hypocarnitinemia."3.74Carnitine-associated encephalopathy caused by long-term treatment with an antibiotic containing pivalic acid. ( Ito, T; Koyama, N; Makino, Y; Sugiura, T; Sugiyama, N, 2007)
" Laboratory evaluation revealed hypoglycemia, hyperammonemia, lactic acidemia, hyperuricemia, and mild dicarboxylic aciduria."3.70Carnitine-acylcarnitine translocase deficiency: metabolic consequences of an impaired mitochondrial carnitine cycle. ( Dorland, L; Duran, M; IJlst, L; Muntau, AC; Roscher, AA; Röschinger, W; Wanders, RJ, 2000)
" Serum L-carnitine levels normalized after correction; sequelae included seizures in two patients, hemiparesis in one patient, normal outcome in one patient, and death in one patient."3.69MR in children with L-carnitine deficiency. ( Barrow, M; Castillo, M; Mukherji, SK; Smith, M; Thompson, JE, 1996)
"When ddY mice were pretreated with L-carnitine (5, 10 or 20 mmol/kg), clonic as well as tonic seizures induced by pentylenetetrazol (PTZ) were dose-dependently suppressed."3.69Suppression of pentylenetetrazol-induced seizures by carnitine in mice. ( Igisu, H; Ikeda, M; Iryo, Y; Matsuoka, M; Yu, Z, 1997)
" Administration of ammonium acetate (15 mmol/kg) to mice caused seizures, elevation of blood ammonia and urea concentrations, and marked alterations of brain energy metabolites."3.68Comparison of the effects of L-carnitine, D-carnitine and acetyl-L-carnitine on the neurotoxicity of ammonia. ( Igisu, H; Matsuoka, M, 1993)
"Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most prevalent encephalopathy in Japanese children."1.51Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study. ( Fukui, KO; Ishiguro, A; Kashii, H; Kubota, M; Terashima, H, 2019)
"No further seizures were noted by day 5."1.51A newborn with seizures born to a mother diagnosed with primary carnitine deficiency. ( Chen, S; Hu, Y; Huang, Y; Lin, J; Lin, Z; Nan, Y; Zhou, X, 2019)
"Valproic acid is a broad-spectrum anticonvulsant that has also gained attention in the psychiatric setting."1.46L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report. ( Fagiolino, P; Guevara, N; Maldonado, C; Silveira, A; Vázquez, M, 2017)
"Patient with symptomatic generalized epilepsy may be particularly good candidates for this type of dietary treatment."1.40Ketogenic diet in adolescents and adults with epilepsy. ( Nei, M; Ngo, L; Sirven, JI; Sperling, MR, 2014)
"At 6 weeks of age she started with convulsions reaching up to 20 myoclonic seizures a day."1.34[Glucose transponer type 1 deficiency síndrome (GLUT-1 SD) treated with ketogenic diet. Report of one case]. ( Cabello, JF; Colombo, MC; Cornejo, VE; Raimann, EB, 2007)
"Her symptoms consisted of a few convulsions between 2."1.33[Glutaric aciduria type 1 with normal evolution: follow-up of one case until adult age]. ( Garcia-Segura, JM; Merinero, B; Pascual-Castroviejo, I; Pascual-Pascual, SI; Ugarte, M; Velazquez, R; Viaño, J, 2005)
"Predominant clinical features include microcephaly, hydrocephalus, seizures, and white-matter changes on magnetic resonance imaging in early-onset cases."1.31Practical management of combined methylmalonicaciduria and homocystinuria. ( Bodamer, OA; Smith, DL, 2002)
"A boy had neonatal seizure, lethargy, and metabolic acidosis at presentation."1.30Very long chain acyl-coenzyme A dehydrogenase deficiency in two siblings: evolution after prenatal diagnosis and prompt management. ( Brivet, M; Hubinont, C; Sluysmans, T; Tuerlinckx, D; Verellen-Dumoulin, C; Vianey-Saban, C, 1997)
"Carnitine levels in CSF were 1/10 compared with serum in normal febrile children."1.30CSF levels of carnitine in children with meningitis, neurologic disorders, acute gastroenteritis, and seizure. ( Gruener, N; Lerner, A; Shinawi, M, 1998)
"Both convulsions and mortality percentages are more significantly reduced in treated animals with these two substances in combination rather than separately."1.28Protective synergic effect of coenzyme Q10 and carnitine on hyperbaric oxygen toxicity. ( Bertelli, A; Bertelli, AA; Giovannini, L; Spaggiari, P, 1990)

Research

Studies (41)

TimeframeStudies, this research(%)All Research%
pre-19908 (19.51)18.7374
1990's14 (34.15)18.2507
2000's9 (21.95)29.6817
2010's10 (24.39)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Maldonado, C1
Guevara, N1
Silveira, A1
Fagiolino, P1
Vázquez, M1
Fukui, KO1
Kubota, M1
Terashima, H1
Ishiguro, A1
Kashii, H1
Chen, S2
Hu, Y1
Huang, Y1
Nan, Y1
Zhou, X1
Lin, J1
Lin, Z1
Felker, D1
Lynn, A1
Wang, S1
Johnson, DE1
Nei, M1
Ngo, L1
Sirven, JI1
Sperling, MR1
Villalba Martínez, G1
Fernández-Candil, JL1
Vivanco-Hidalgo, RM1
Pacreu Terradas, S1
León Jorba, A1
Arroyo Pérez, R1
Zeiler, FA1
Sader, N1
Gillman, LM1
West, M1
Zelnik, N1
Isler, N1
Goez, H1
Shiffer, M1
David, M1
Shahar, E1
Napolitano, C1
Scaglianti, M1
Scalambra, E1
Manfredini, S1
Ferraro, L1
Beggiato, S1
Vertuani, S1
Das, S1
Joardar, S1
Chatterjee, R1
Guha, G1
Hashmi, MA1
Cansu, A1
Serdaroglu, A1
Biberoglu, G1
Tumer, L1
Hirfanoglu, TL1
Ezgu, FS1
Hasanoglu, A1
Listernick, R1
Smith, DL1
Bodamer, OA1
HOSEIN, EA2
Pascual-Castroviejo, I1
Pascual-Pascual, SI1
Merinero, B1
Ugarte, M1
Garcia-Segura, JM1
Viaño, J1
Velazquez, R1
Cornejo, VE1
Cabello, JF1
Colombo, MC1
Raimann, EB1
Makino, Y1
Sugiura, T1
Ito, T1
Sugiyama, N1
Koyama, N1
Maegawa, GH1
Poplawski, NK1
Andresen, BS1
Olpin, SE1
Nie, G1
Clarke, JT1
Teshima, I1
Gozsy, B1
Kato, L1
Roy, PB1
Kato, G1
Bernardi, M1
Bertolini, A1
Ferrari, F1
Greggia, A1
Corbett, R1
Leonard, BE1
Ater, SB1
Swinyard, EA1
Tolman, KG1
Madsen, JA1
Matsuo, F1
Fariello, RG1
Zeeman, E1
Golden, GT1
Reyes, PT1
Ramacci, T1
Igisu, H4
Matsuoka, M4
Iryo, Y2
Van Wouwe, JP1
Thompson, JE1
Smith, M1
Castillo, M1
Barrow, M1
Mukherji, SK1
Herink, J1
Yu, Z1
Ikeda, M1
Sluysmans, T1
Tuerlinckx, D1
Hubinont, C1
Verellen-Dumoulin, C1
Brivet, M1
Vianey-Saban, C1
Shinawi, M1
Gruener, N1
Lerner, A1
Steen, C1
Baumgartner, ER1
Duran, M2
Lehnert, W1
Suormala, T1
Fingerhut, R1
Stehn, M1
Kohlschütter, A1
Röschinger, W1
Muntau, AC1
Dorland, L1
IJlst, L1
Wanders, RJ1
Roscher, AA1
Sanford, MG1
Ryan, C1
Cummings, AD1
Hunt, A1
Hackes, B1
Murakami, K1
Sugimoto, T1
Nishida, N1
Kobayashi, Y1
Kuhara, T1
Matsumoto, I1
Kohriyama, K1
Inoue, N1
Hug, G1
McGraw, CA1
Bates, SR1
Landrigan, EA1
Bertelli, A2
Giovannini, L2
Mian, M1
Spaggiari, PG1
Bertelli, AA1
Spaggiari, P1
Rodriguez-Segade, S1
de la Peña, CA1
Tutor, JC1
Paz, JM1
Fernandez, MP1
Rozas, I1
Del Río, R1
Millington, DS1
Bohan, TP1
Roe, CR1
Yergey, AL1
Liberato, DJ1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075]Phase 142 participants Interventional2003-09-30Completed
Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453]Phase 1/Phase 240 participants (Actual)Interventional2008-04-30Completed
Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266]Phase 294 participants (Actual)Interventional2005-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Anthropometric Measures of Nutritional Status (Body Mass Index [BMI] Z-scores, Weight for Length Ratios, Lean/Fat Mass Via DEXA, Growth Parameters, and Triceps Skinfold Measures)

(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months

Interventiong (Mean)
Lean Mass BaselineLean Mass 3 monthsLean Mass 6 monthsFat Mass BaselineFat Mass 3 monthsFat Mass 6 months
SMA Type 14317.154993.925133.833011.373618.254316.08

Max CMAP Amplitude (Mean)

The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)

,,
InterventionmV (Mean)
Baseline6 months
Cohort 1a Sitters Placebo Then Treatment2.282.32
Cohort 1b Sitters Treatment2.932.37
Cohort 2 Standers and Walkers - Treatment5.526.56

Max CMAP Amplitude Median

The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)

,,
InterventionmV (Median)
Baseline6 months
Cohort 1a Sitters Placebo Then Treatment1.911.44
Cohort 1b Sitters Treatment2.21.8
Cohort 2 Standers and Walkers - Treatment5.35.85

Max CMAP Area (Mean)

The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)

,,
InterventionmVms (Mean)
Baseline6 months
Cohort 1a Sitters Placebo Then Treatment5.465.28
Cohort 1b Sitters Treatment5.455.26
Cohort 2 Standers and Walkers - Treatment14.8516.26

Max CMAP Area (Median)

The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)

,,
InterventionmVms (Median)
Baseline6 months
Cohort 1a Sitters Placebo Then Treatment3.63.74
Cohort 1b Sitters Treatment4.63.4
Cohort 2 Standers and Walkers - Treatment13.6516.85

Modified Hammersmith Change From Baseline to 6 Months

Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months

,
InterventionScore (Mean)
Baseline visit (0 weeks)6 Month visit (V2)Change from Baseline
Cohort 1a Sitters Placebo Then Treatment20.020.60.6
Cohort 1b Sitters Treatment16.616.80.2

Modified Hammersmith Extend Baseline

"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)

InterventionScore (Mean)
Modified Hammersmith Extend at S1 (-4 weeks)Modified Hammersmith Extend at S2 (0 weeks)
Cohort 2 Experimental47.048.3

Reviews

4 reviews available for carnitine and Seizures

ArticleYear
Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity.
    Expert review of clinical pharmacology, 2014, Volume: 7, Issue:2

    Topics: Animals; Anticonvulsants; Bipolar Disorder; Carnitine; Chemical and Drug Induced Liver Injury; Child

2014
Levocarnitine induced seizures in patients on valproic acid: A negative systematic review.
    Seizure, 2016, Volume: 36

    Topics: Anticonvulsants; Carnitine; Databases, Factual; Humans; Seizures; Valproic Acid

2016
Interstitial deletion of 1p22.2p31.1 and medium-chain acyl-CoA dehydrogenase deficiency in a patient with global developmental delay.
    American journal of medical genetics. Part A, 2008, Jun-15, Volume: 146A, Issue:12

    Topics: Acyl-CoA Dehydrogenase; Carnitine; Child; Chromosome Deletion; Chromosomes, Human, Pair 1; Dicarboxy

2008
Protection of the brain by carnitine.
    Sangyo eiseigaku zasshi = Journal of occupational health, 1995, Volume: 37, Issue:2

    Topics: Ammonia; Animals; Brain; Brain Ischemia; Carnitine; Energy Metabolism; Humans; Mice; Seizures; Tauri

1995

Other Studies

37 other studies available for carnitine and Seizures

ArticleYear
L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report.
    The Journal of international medical research, 2017, Volume: 45, Issue:3

    Topics: Adult; Anticonvulsants; Carnitine; Female; Humans; Hyperammonemia; Seizures; Valproic Acid

2017
Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study.
    Brain & development, 2019, Volume: 41, Issue:7

    Topics: Brain Diseases; Carnitine; Case-Control Studies; Child, Preschool; Diagnosis, Differential; Disease

2019
A newborn with seizures born to a mother diagnosed with primary carnitine deficiency.
    BMC pediatrics, 2019, 03-18, Volume: 19, Issue:1

    Topics: Brain; Cardiomyopathies; Carnitine; Electroencephalography; Female; Fetal Diseases; Humans; Hyperamm

2019
Ketogenic diet in adolescents and adults with epilepsy.
    Seizure, 2014, Volume: 23, Issue:6

    Topics: Adolescent; Adult; Carnitine; Child; Cholesterol; Diet, Ketogenic; Electrocardiography; Epilepsies,

2014
Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
    Revista espanola de anestesiologia y reanimacion, 2015, Volume: 62, Issue:5

    Topics: Anesthesia, General; Anesthesia, Local; Anticonvulsants; Aphasia; Benzodiazepines; Brain Diseases; B

2015
Vigabatrin, lamotrigine, topiramate and serum carnitine levels.
    Pediatric neurology, 2008, Volume: 39, Issue:1

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Female; Fructose; Humans; Infant; L

2008
Carnitine conjugate of nipecotic acid: a new example of dual prodrug.
    Molecules (Basel, Switzerland), 2009, Aug-31, Volume: 14, Issue:9

    Topics: Animals; Brain; Carnitine; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Mice; Nipe

2009
Rare magnetic resonance imaging findings in medium-chain acyl-coenzyme A dehydrogenase deficiency.
    Pediatric neurology, 2011, Volume: 45, Issue:3

    Topics: Acyl-CoA Dehydrogenase; Anticonvulsants; Basal Ganglia; Brain; Brain Ischemia; Carnitine; Cerebral I

2011
Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine.
    Epileptic disorders : international epilepsy journal with videotape, 2011, Volume: 13, Issue:4

    Topics: Adolescent; Anticonvulsants; Carbamazepine; Carnitine; Child; Child, Preschool; Chromatography, High

2011
A 14-year-old boy with vomiting.
    Pediatric annals, 2012, Volume: 41, Issue:5

    Topics: Abdominal Pain; Adolescent; Brain Ischemia; Carnitine; Cognition Disorders; Diagnosis, Differential;

2012
Practical management of combined methylmalonicaciduria and homocystinuria.
    Journal of child neurology, 2002, Volume: 17, Issue:5

    Topics: Adolescent; Adult; Betaine; Carnitine; Child; Child, Preschool; Female; Folic Acid; Gastrointestinal

2002
The isolation of gamma-butyrobetaine, crotonbetaine and carnitine from brains of animals killed during induced convulsions.
    Archives of biochemistry and biophysics, 1963, Volume: 100

    Topics: Alkaloids; Animals; Betaine; Brain; Carnitine; Folic Acid; Seizures; Vitamin B Complex

1963
[Glutaric aciduria type 1 with normal evolution: follow-up of one case until adult age].
    Neurologia (Barcelona, Spain), 2005, Volume: 20, Issue:4

    Topics: Basal Ganglia; Brain; Brain Chemistry; Brain Diseases, Metabolic, Inborn; Carnitine; Cells, Cultured

2005
[Glucose transponer type 1 deficiency síndrome (GLUT-1 SD) treated with ketogenic diet. Report of one case].
    Revista medica de Chile, 2007, Volume: 135, Issue:5

    Topics: Anticonvulsants; Blood Glucose; Carbohydrate Metabolism, Inborn Errors; Carnitine; Dietary Fats; Ery

2007
Carnitine-associated encephalopathy caused by long-term treatment with an antibiotic containing pivalic acid.
    Pediatrics, 2007, Volume: 120, Issue:3

    Topics: Acidosis; Anti-Bacterial Agents; Brain Diseases, Metabolic; Carnitine; Cephalosporins; Humans; Hypog

2007
Effect of prolonged treatment with electroshock, metrazol, carnitine and anectine on the capillary permeability.
    International journal of neuropsychiatry, 1967, Volume: 3, Issue:2

    Topics: Animals; Capillary Permeability; Carnitine; Electric Stimulation; Electroshock; Female; Histamine; M

1967
[Activation of the acetylation in vivo of sulfamide by DL-acetylcarnitine].
    Bollettino della Societa italiana di biologia sperimentale, 1967, Sep-30, Volume: 43, Issue:18

    Topics: Acetates; Animals; Carbon Tetrachloride Poisoning; Carnitine; Chemical and Drug Induced Liver Injury

1967
Effects of carnitine on changes caused by chronic administration of alcohol.
    Neuropharmacology, 1984, Volume: 23, Issue:2B

    Topics: Alcoholism; Animals; Ca(2+) Mg(2+)-ATPase; Calcium-Transporting ATPases; Carnitine; Exploratory Beha

1984
Effects of SKF525A, phenobarbital, fasting, and carnitine on the anticonvulsant activity and neurotoxicity of valproate in mice.
    Epilepsia, 1984, Volume: 25, Issue:5

    Topics: Animals; Carnitine; Fasting; Male; Mice; Mice, Inbred Strains; Nervous System; Phenobarbital; Proadi

1984
Transient seizure activity induced by acetylcarnitine.
    Neuropharmacology, 1984, Volume: 23, Issue:5

    Topics: Acetylcarnitine; Animals; Atropine; Carnitine; Cerebral Cortex; Electroencephalography; gamma-Aminob

1984
Comparison of the effects of L-carnitine, D-carnitine and acetyl-L-carnitine on the neurotoxicity of ammonia.
    Biochemical pharmacology, 1993, Jul-06, Volume: 46, Issue:1

    Topics: Acetates; Acetylcarnitine; Ammonia; Animals; Brain; Carnitine; Male; Mice; Neurotoxins; Seizures; St

1993
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
MR in children with L-carnitine deficiency.
    AJNR. American journal of neuroradiology, 1996, Volume: 17, Issue:8

    Topics: Adolescent; Carnitine; Cause of Death; Cerebral Hemorrhage; Cerebral Infarction; Cerebral Ventricles

1996
Enhancing effect of L-carnitine on some abnormal signs induced by pentylenetetrazol.
    Acta medica (Hradec Kralove), 1996, Volume: 39, Issue:2

    Topics: Animals; Blood-Brain Barrier; Carnitine; Convulsants; Male; Pentylenetetrazole; Rats; Rats, Wistar;

1996
Suppression of pentylenetetrazol-induced seizures by carnitine in mice.
    Naunyn-Schmiedeberg's archives of pharmacology, 1997, Volume: 355, Issue:4

    Topics: Animals; Brain; Carnitine; Dose-Response Relationship, Drug; Energy Metabolism; Male; Mice; Pentylen

1997
Very long chain acyl-coenzyme A dehydrogenase deficiency in two siblings: evolution after prenatal diagnosis and prompt management.
    The Journal of pediatrics, 1997, Volume: 131, Issue:3

    Topics: Acidosis; Acyl-CoA Dehydrogenase, Long-Chain; Amniocentesis; Carnitine; Diagnosis, Differential; Fat

1997
CSF levels of carnitine in children with meningitis, neurologic disorders, acute gastroenteritis, and seizure.
    Neurology, 1998, Volume: 50, Issue:6

    Topics: Adolescent; Carnitine; Child; Child, Preschool; Female; Fever; Gastroenteritis; Humans; Infant; Infa

1998
Metabolic stroke in isolated 3-methylcrotonyl-CoA carboxylase deficiency.
    European journal of pediatrics, 1999, Volume: 158, Issue:9

    Topics: Amino Acid Metabolism, Inborn Errors; Carbon-Carbon Ligases; Carnitine; Diet, Protein-Restricted; Fa

1999
Carnitine-acylcarnitine translocase deficiency: metabolic consequences of an impaired mitochondrial carnitine cycle.
    Clinica chimica acta; international journal of clinical chemistry, 2000, Volume: 298, Issue:1-2

    Topics: Ammonia; Cardiac Output, Low; Carnitine; Carnitine Acyltransferases; Cells, Cultured; Coma; Consangu

2000
Protocols for identifying drug-nutrient interactions in patients: the role of the dietitian.
    Journal of the American Dietetic Association, 2002, Volume: 102, Issue:5

    Topics: Adolescent; Adult; Anticonvulsants; Biotin; Calcium; Carnitine; Dietetics; Edema; Folic Acid; Food-D

2002
Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy.
    Brain & development, 1992, Volume: 14, Issue:3

    Topics: Brain Diseases; Carnitine; Cerebral Palsy; Child; Chronic Disease; Female; Gas Chromatography-Mass S

1992
Suppression of neurotoxicity of ammonia by L-carnitine.
    Brain research, 1991, Dec-20, Volume: 567, Issue:2

    Topics: Ammonia; Animals; Behavior, Animal; Brain Chemistry; Carnitine; Energy Metabolism; Male; Mice; Mice,

1991
Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children.
    The Journal of pediatrics, 1991, Volume: 119, Issue:5

    Topics: Analysis of Variance; Carbamazepine; Carnitine; Child; Drug Combinations; Fatty Acids; Fatty Acids,

1991
Protective action of propionyl-L-carnitine on toxicity induced by hyperbaric oxygen.
    Drugs under experimental and clinical research, 1990, Volume: 16, Issue:10

    Topics: Animals; Carnitine; Hyperbaric Oxygenation; Lung Diseases; Male; Mice; Seizures

1990
Protective synergic effect of coenzyme Q10 and carnitine on hyperbaric oxygen toxicity.
    International journal of tissue reactions, 1990, Volume: 12, Issue:3

    Topics: Animals; Carnitine; Coenzymes; Drug Synergism; Drug Therapy, Combination; Hyperbaric Oxygenation; Ma

1990
Carnitine deficiency associated with anticonvulsant therapy.
    Clinica chimica acta; international journal of clinical chemistry, 1989, May-15, Volume: 181, Issue:2

    Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Carnitine; Cerebral Palsy; Drug Therapy, Co

1989
Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry.
    Clinica chimica acta; international journal of clinical chemistry, 1985, Jan-15, Volume: 145, Issue:1

    Topics: Adolescent; Carnitine; Child; Child, Preschool; Chromatography, High Pressure Liquid; Humans; Isomer

1985